www.ustoo.org    |   Donate  |    View in Browser

Made possible by a charitable contribution from Bayer
Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.


We hope you are doing well and helping to raise awareness for prostate cancer throughout the month of September.

We’re pleased to provide you with  some of the latest Prostate Cancer News You Can Use . In addition to the following updates and information that may be of interest to you, the titles of prostate cancer news articles are listed below along with a link to the Us TOO web page that provides access to the full text for each article.

If you need any conversation-starters about September being  Prostate Cancer Awareness Month, here are some quick facts about the disease:
  • Nearly 175,000 men will be diagnosed with prostate cancer in 2019
  • More than 31,000 men in the U.S. will die this year from prostate cancer; it’s the second largest cancer killer of men following lung cancer
  • Prostate cancer has no symptoms until it’s advanced
  • The disease is always treatable; but if detected early, prostate cancer is often curable

Find more information at:  www.ustoo.org/Facts-And-Stats. F ollow us on Facebook or Twitter and share our daily #ProstateCancerAwarenessMonth posts featuring stats and resources.  

We’d like to thank everyone who helped to make the  15th Annual SEA Blue Chicago Prostate Cancer Walk and Run a huge success! More than 1,000 people gathered in Lincoln Park to raise awareness for prostate cancer along with funds to help Us TOO provide Support, Education, and Advocacy for the prostate cancer community at no charge. The SEA Blue website is open for donations until October 15.

Free registration is now open for both of the Us TOO Pathways educational events.  Prostate Cancer Pathways is a new, dynamic educational event and webcast series from Us TOO International for men with prostate cancer and their loved ones. The 2019 two-event Pathways series will include panel discussions featuring medical experts and patients addressing topics that are most important to men with prostate cancer, as determined by survey results from Us TOO support group leaders. Plan to attend in-person or watch the webcast with live audio and video from each of the two events:

1.       The Pathways event in Detroit is on Saturday, Oct. 12; CLICK HERE to
r egister for the webcast, or if you will be in Detroit to attend in person,
CLICK HERE to register.

2.      The Pathways event in Chicago is on Saturday, Nov. 9; CLICK HERE t o register for either online or in person attendance. For any questions on registration call Us TOO at 800-808-7866.

Th e Prostate Cancer Foundation has recently updated their Patient Guide to reflect the very latest research and discoveries for prostate cancer patients. CLICK HERE to download an updated digital copy. PCF is also offering "The Science of Living Well, Beyond Cancer."  CLICK HERE to download your free PDF.

Check out the latest issue of the  EUROPA UOMO newsletter for prostate cancer initiatives in Europe. And participate in the European Prostate Cancer  Quality of Life Survey from Europa Uomo. The success of this online survey depends on a strong response rate by its member organizations in 27 countries.

IRONMAN  is a registry recruiting 5,000 men with advanced prostate cancer from nine countries. More than 366,000 men die of prostate cancer globally every year. Research on a man's type of prostate cancer, treatment and side effects will help inform what causes prostate cancer, how to stop or slow its progression, and how to provide the best possible care to enable men to live the best quality life possible.  CLICK HERE for details. 

The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with metastatic and/or advanced prostate cancer. Patients can join online and participate by sharing their medical information and samples. The project’s goal is to release new data to help researchers better understand metastatic and advanced prostate cancer, and accelerate discoveries.  CLICK HERE to learn more.

BRCA Blue is an initiative to help educate patients and caregivers about the  connection between BRCA gene mutations and prostate cancer. While some people may have heard about BRCA genes and their relationship to breast and ovarian cancers, research has shown a connection to other cancers as well – including prostate cancer. Men who have a BRCA mutation are at a higher risk for developing prostate cancer than men without a BRCA mutation. To learn more about this important gene visit BRCABlue.com .
Recently, Congress expanded the geographic limits for exposure to Agent Orange. Veterans who served on vessels within 12 nautical miles seaward from the demarcation line of waters of Vietnam and Cambodia as defined in Public Law 116-23 (Blue Water Navy) between January 9, 1962, and May 7, 1975, are presumed to have been exposed to herbicides such as Agent Orange and may be entitled to service connection for conditions related to that exposure. Read more in the press release and find additional information including a list of conditions in the fact sheet.

Weill Cornell Medicine, New York-Presbyterian Hospital, Columbia University Irving Medical Center and Memorial Sloan Kettering Cancer Center will co-host the 2nd Annual NYC Prostate Cancer Summit on Saturday, September 21, at the New York Academy of Medicine (1216 5th Avenue, New York, NY 10029). This FREE patient education event will last from 8AM – 2PM and cover topics such as the latest prostate cancer treatments and technologies, coping with side effects, clinical trials, genetics and more. CLICK HERE to register.
Malecare is hosting a Prostate Cancer Patient Conference on October 5. Presentations throughout the day will feature 12 physicians, including six from Memorial Sloan Kettering, breakfast, lunch, snacks and drinks. Discounted rooms are provided at the Intercontinental Barclay hotel in Manhattan. Register with the promotion code "UsTOO" for a 50% discount. CLICK HERE for event information and registration.

The National Alliance of State Prostate Cancer Coalitions – “ The Prostate Cancer Alliance”- is pleased to present its 15th Annual Meeting GALA on Saturday, October 19, 2019 at 6:30 pm. CLICK HERE for more information.

Registration is now open for Prostate Cancer International's 4th FREE conference for patients and caregivers on Saturday, November 2nd in Virginia Beach, VA. CLICK HERE for more information.
Consider adding to your prostate cancer knowledge with a new book by leading expert Dr. Jeffrey Albaugh, who is also a regular contributor to the  Hot SHEET  Between the Sheets column. Featuring patient stories about hope and guidance for those facing prostate cancer,  Reclaiming Sex & Intimacy After Prostate Cancer, A Guide for Men and Their Partners, 2nd Edition helps men cope with the challenges of a prostate cancer diagnosis.  CLICK HERE for more information .


Please note that the content below lists only the title of the article rather than a direct link to the content. For access to the full article  CLICK HERE.

  • FDA Grants Priority Review to Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer

  • Findings from Cedars-Sinai Medical Center Has Provided New Information about Prostatectomy (Association of Social Media Presence with Online Physician Ratings and Surgical Volume Among California Urologists: Observational Study)

  • New Prostate Cancer Study Findings Have Been Reported from Hannover Medical School (Systematic evaluation of written health information on PSA based screening in Germany)

  • Risks of novel oral prostate cancer therapies and pre-existing conditions

  • Researchers identify a possible therapeutic target for Kennedy’s disease and prostate cancer

  • Study Data from University of Kentucky Update Knowledge of Prostate Cancer (New developments in mechanisms of prostate cancer progression)

  • New Prostate Cancer Findings from Osaka University Graduate School of Medicine Reported (Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer)

  • Blocking kinase could provide treatment for prostate cancer

  • Study Data from Polytechnic University of the Marche Region Update Knowledge of Prostate Cancer (Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers)

  • Findings from University of Washington Provides New Data on Prostate Cancer (The development and comparative effectiveness of a patient-centered prostate biopsy report: a prospective, randomized study)

  • Data from University of North Carolina Advance Knowledge in Prostate Cancer (Proton Therapy for Prostate Cancer: a Review of the Rationale, Evidence, and Current State)

  • Research from University of Utah Reveals New Findings on Prostate Cancer

  • Presidential Message on National Prostate Cancer Awareness Month


The journal Cancer – a journal of the American Cancer Society – published results of the PROCEED registry, which found that men with advanced prostate cancer with low PSA had a median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). PROCEED is the largest real-world study of immunotherapy. Read the Journal article and the press release.

Data Analysis Showed Additional Overall Survival Benefit with Sipuleucel-T in African American Patients. CLICK HERE for video.

The Prostate Cancer Misdiagnosis Elimination Act has been reported out of both the House Ways and Means Committee (as part of the HEARTS Act, H.R. 3429) and Energy and Commerce Committee (as part of the REACH Act, H.R. 2328) this past summer. The Prostate Cancer Misdiagnosis Elimination Act amends the statute to provide Medicare coverage for DSPA testing of all (putative) positive prostate cancer biopsies. The bill ensures that the right man gets the right treatment, or no treatment at all by identifying false positive and false negative biopsies. The Congressional Budget Office (CBO) recently reevaluated the bill saving over 10-fold from about $7 million to $74 million over 10 years. Us TOO and several other groups support this bill, and we hope to see floor action soon. 

Watch for the October issue of the Us TOO Hot SHEET newsletter, and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.

All the best,

Chuck Strand, Chief Executive Officer
James Hutson, Development Director
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
Tim Mix, Communications Director